P3-172: Search for neuroimaging biomarkers of amnestic mild cognitive impairment: A multimodal structural and functional neuroimaging study

2015 ◽  
Vol 11 (7S_Part_15) ◽  
pp. P695-P696
Author(s):  
Himanshu Joshi ◽  
Srikala Bharath ◽  
John P. John ◽  
Rakesh Balachandar ◽  
Shilpa Sadanand ◽  
...  
2017 ◽  
Vol 25 (2) ◽  
pp. 158-169 ◽  
Author(s):  
Srikala Bharath ◽  
Himanshu Joshi ◽  
John P. John ◽  
Rakesh Balachandar ◽  
Shilpa Sadanand ◽  
...  

2013 ◽  
Vol 28 (3) ◽  
pp. 129 ◽  
Author(s):  
Madhavi Tripathi ◽  
Manjari Tripathi ◽  
Abhinav Jaimini ◽  
Suman Kushwaha ◽  
Rajnish Sharma ◽  
...  

2011 ◽  
Vol 49 (7) ◽  
pp. 2060-2070 ◽  
Author(s):  
Mischa de Rover ◽  
Valentino A. Pironti ◽  
Jonathan A. McCabe ◽  
Julio Acosta-Cabronero ◽  
F. Sergio Arana ◽  
...  

2017 ◽  
Vol 57 (2) ◽  
pp. 447-459 ◽  
Author(s):  
Ana Espinosa ◽  
Montserrat Alegret ◽  
Pedro Pesini ◽  
Sergi Valero ◽  
Asunción Lafuente ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-17 ◽  
Author(s):  
Ai-Ling Lin ◽  
Angela R. Laird ◽  
Peter T. Fox ◽  
Jia-Hong Gao

Multimodal magnetic resonance imaging (MRI) techniques have been developed to noninvasively measure structural, metabolic, hemodynamic and functional changes of the brain. These advantages have made MRI an important tool to investigate neurodegenerative disorders, including diagnosis, disease progression monitoring, and treatment efficacy evaluation. This paper discusses recent findings of the multimodal MRI in the context of surrogate biomarkers for identifying the risk for AD in normal cognitive (NC) adults, brain anatomical and functional alterations in amnestic mild cognitive impairment (aMCI), and Alzheimer's disease (AD) patients. Further developments of these techniques and the establishment of promising neuroimaging biomarkers will enhance our ability to diagnose aMCI and AD in their early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials.


Sign in / Sign up

Export Citation Format

Share Document